2021
Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases
Huang RSP, Haberberger J, McGregor K, Mata DA, Decker B, Hiemenz MC, Lechpammer M, Danziger N, Schiavone K, Creeden J, Graf RP, Strowd R, Lesser GJ, Razis ED, Bartsch R, Giannoudis A, Bhogal T, Lin NU, Pusztai L, Ross JS, Palmieri C, Ramkissoon SH. Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. The Oncologist 2021, 26: 835-844. PMID: 34105210, PMCID: PMC8488784, DOI: 10.1002/onco.13855.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBrain NeoplasmsGenomicsHumansRetrospective StudiesTriple Negative Breast NeoplasmsConceptsComprehensive genomic profilingPD-L1 immunohistochemistryBrain metastasesTumor mutational burdenPrimary breast carcinomaRelevant genomic alterationsBreast carcinomaPrimary tumorHigh prevalenceMutational burdenCerebrospinal fluidTissue acquisitionCatalytic polypeptide-like (APOBEC) mutational signatureGenomic alterationsPrimary breast carcinoma specimensHigh tumor mutational burdenGenomic profilingTriple-negative breast carcinomaTNBC brain metastasisCohort of patientsBrain metastasis samplesBreast carcinoma specimensHigher positive rateHigh microsatellite instabilityApolipoprotein B mRNA editing enzyme
2010
Nomogram to Predict Subsequent Brain Metastasis in Patients With Metastatic Breast Cancer
Graesslin O, Abdulkarim BS, Coutant C, Huguet F, Gabos Z, Hsu L, Marpeau O, Uzan S, Pusztai L, Strom EA, Hortobagyi GN, Rouzier R, Ibrahim NK. Nomogram to Predict Subsequent Brain Metastasis in Patients With Metastatic Breast Cancer. Journal Of Clinical Oncology 2010, 28: 2032-2037. PMID: 20308667, DOI: 10.1200/jco.2009.24.6314.Peer-Reviewed Original ResearchConceptsSubsequent brain metastasesBrain metastasesMetastatic breast cancerBreast cancerPatient populationMethods Electronic medical recordsStage IV breast cancerHuman epidermal growth factor receptor 2Shorter disease-free survivalEpidermal growth factor receptor 2Multivariate logistic regression analysisDisease-free survivalGrowth factor receptor 2Logistic regression analysisDesign of trialsFactor receptor 2Cross Cancer InstituteElectronic medical recordsInstitutional review boardMetastatic diseaseMetastatic sitesPrevention trialsPrognostic featuresClinical nomogramMedical records